[Skip to content]

Royal Brompton & Harefield NHS Foundation Trust
Our research
Search our Site
Bronchiectasis treatments

Our research

Active research studies

The Trust hosts a variety of research studies covering the breadth of its clinical practice. These are funded by a variety of sponsors including National Institute for Health Research (NIHR), UK research councils, European funding agencies, research charities and industry. 


Below is a list of approved projects that are currently recruiting volunteers.

  

Research studies

Specialty CategoryResearch titleStudy contact informationMore info
Chronic obstructive pulmonary diseaseIs gait speed and sarcopenia prognostic in chronic respiratory diseaseDr Jane CanavanMore info
Chronic obstructive pulmonary diseasePHASE 1B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF QR-010 IN SUBJECTS WITH HOMOZYGOUS ?F508 CYSTIC FIBROSISMahitha Gammadi and Rebecca DobraMore info
Chronic suppurative lung diseaseA phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis harbouring one F508del CFTR mutation and a second gating (class III) mutationSandra ScottMore info
Chronic suppurative lung diseaseA Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation -Sandra ScottMore info
Chronic suppurative lung diseaseMulti-center, randomized, double-blind, placebo-controlled phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult ?F508 homozygous Cystic Fibrosis patientsSandra Scott and Dr Rebecca DobraMore info
Chronic suppurative lung diseaseHome monitoring to predict exacerbations in Cystic Fibrosis - SMART CAREAndy JonesMore info
Chronic suppurative lung diseaseA Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic FibrosisKatherine HubandMore info
Chronic suppurative lung diseaseNIHR BioResource - Rare DiseasesJohn Wort or Natalie DormandMore info
Chronic suppurative lung diseaseA Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long-term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation - Vx15-770-123 (Clare SaundersMore info
Chronic suppurative lung diseaseVX14-661-109: A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508deSandra ScottMore info

See details of the Trust’s performance for all clinical trials reported to the NIHR (PDF, 276KB), for the set-up and delivery of studies in the period 1 October 2016 to 30 September 2017.

Royal Brompton

Sydney Street,
London SW3 6NP
Tel: +44 (0)20 7352 8121

Harefield